Retatrutide
Investigational triple receptor agonist with a substantial clinical development programme in obesity and metabolic disease.
Mechanism & research rationale
Retatrutide is designed to agonize GIP, GLP-1 and glucagon receptors. The programme studies how combined incretin and glucagon-receptor signalling affects energy balance, glycaemia, appetite and body weight.
Human evidence
A peer-reviewed 2023 phase 2 randomized trial in 338 adults with obesity reported substantial mean weight reductions over 48 weeks and established the basis for phase 3 testing. By 2026, Lilly had announced positive phase 3 topline results from multiple TRIUMPH studies, including obesity populations with and without type 2 diabetes and cardiovascular disease. Full peer-reviewed publication of every phase 3 dataset may lag company topline announcements.
Preclinical / translational evidence
Mechanistic and preclinical work informed receptor selection and metabolic hypotheses, but the most decision-relevant evidence is now from randomized human trials.
Key limitations
- Retatrutide remains investigational; it should not be represented as an approved medicine.
- Topline company announcements are less complete than full peer-reviewed trial reports.
- Safety/tolerability findings need to be interpreted within controlled clinical trials, not extrapolated to unregulated products.